Brevan Howard Capital Management
PRME icon

Brevan Howard Capital Management’s Prime Medicine PRME Stock Holding History

Brevan Howard Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.6K Buy
+12,910
New +$42.9K ﹤0.01% 2016
2026
Q1 		– Sell
-56,088
Closed -$195K – 2418
2025
Q4 		$195K Sell
56,088
-6,154
-10% -$27.4K ﹤0.01% 1589
2025
Q3 		$345K Buy
+62,242
New +$253K ﹤0.01% 1491
2025
Q2 		– Sell
-28,478
Closed -$56.7K – 1977
2025
Q1 		$56.7K Buy
+28,478
New +$72.6K ﹤0.01% 1086

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Brevan Howard Capital Management's PRME Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Prime Medicine (PRME) in Q2 2026: 12,910 shares worth $47.6K. The stake represents ﹤0.01% of the portfolio and ranks #2016 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in PRME as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in PRME in Q1 2025 and has held it in 4 quarters since. The position peaked at $345K in Q3 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Brevan Howard Capital Management held 12,910 shares of Prime Medicine worth $47.6K as of Q2 2026.
  • Prime Medicine was a new Brevan Howard Capital Management position in Q2 2026.
  • Prime Medicine made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #2016 holding.
  • Brevan Howard Capital Management first reported a position in Prime Medicine in Q1 2025 and has held it in 4 quarters since.
  • Brevan Howard Capital Management's Prime Medicine position peaked at $345K in Q3 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.